Are we at the Goal Line with the Novel Oral Anticoagulants and Have We Reached the End of the Line for Dronedarone and Vernakalant – or is There More to Come?

Publisher： Bentham Science Publishers

E-ISSN： 1875-6557|10|4|315-316

ISSN： 1573-403X

Source： Current Cardiology Reviews, Vol.10, Iss.4, 2014-11, pp. : 315-316

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial from Editor-in-Chief (Novel Oral Anticoagulants in the Treatment of Pulmonary Embolism: Are We There Yet?)

By  

Current Respiratory Medicine Reviews, Vol. 9, Iss. 3, 2013-06 ,pp. : 147-148

Bentham Science Publishers

Access to resources Recommend Favorite

Magnetic resonance colonography in clinical use: How far have we come?

By Achiam Michael   Thomsen Henrik   Rosenberg Jacob  

Scandinavian Journal of Gastroenterology, Vol. 44, Iss. 5, 2009-05 ,pp. : 518-526

Informa Healthcare

Access to resources Recommend Favorite

Evidence-Based Endocrinology: How Far Have We Come?

By Montori Victor M.  

Treatments in Endocrinology, Vol. 3, Iss. 1, 2004-01 ,pp. : 1-10

Adis International

Access to resources Recommend Favorite

Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation

By  

Current Cardiology Reviews, Vol. 12, Iss. 4, 2016-11 ,pp. : 330-335

Bentham Science Publishers

Access to resources Recommend Favorite

Are Some Anticoagulants More Equal Than Others? - Evaluating the Role of Novel Oral Anticoagulants in AF Ablation

By  

Current Cardiology Reviews, Vol. 12, Iss. 4, 2016-08 ,pp. : 330-335

Bentham Science Publishers

Access to resources Recommend Favorite